S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
NASDAQ:GMDA

Gamida Cell (GMDA) Stock Price, News & Analysis

$0.06
-0.28 (-82.55%)
(As of 03/27/2024 ET)
Today's Range
$0.05
$0.08
50-Day Range
$0.06
$0.46
52-Week Range
$0.05
$2.51
Volume
124.37 million shs
Average Volume
4.89 million shs
Market Capitalization
$6.25 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.75

Gamida Cell MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
7,923.6% Upside
$4.75 Price Target
Short Interest
Bearish
10.38% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.03mentions of Gamida Cell in the last 14 days
Based on 17 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.66) to ($0.55) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.47 out of 5 stars

GMDA stock logo

About Gamida Cell Stock (NASDAQ:GMDA)

Gamida Cell Ltd. is a biotechnology company specializing in developing and commercializing innovative cell therapies. With a mission to transform the lives of patients with severe hematologic and solid tumor cancers, Gamida Cell is dedicated to harnessing the power of cell therapy to provide effective and personalized treatment options.

Headquartered in Jerusalem, Israel, Gamida Cell operates globally, focusing on developing and delivering breakthrough therapies to address significant unmet medical needs. The company's flagship product, Omidubicel, is an investigational advanced cell therapy designed to enhance the outcome of bone marrow transplantation and improve the standard of care for patients with hematologic malignancies.

Gamida Cell's products and services revolve around cell therapy, with a particular emphasis on expanding and enhancing the therapeutic potential of stem cells. By leveraging its proprietary NAM-based cell expansion technology platform, the company aims to increase the number and functionality of cells for transplantation, leading to improved patient outcomes.

The company primarily targets patients with blood cancers, including leukemia, lymphoma, and myeloma, where traditional treatment options often fall short. Gamida Cell's innovative approach has garnered recognition within the medical community and has received several notable achievements, milestones, and awards. For instance, in 2022, Gamida Cell was granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for Omidubicel, highlighting the therapy's potential to address a critical medical need.

It is important to note that stock performance is influenced by various factors, including news and events specific to the company. Recent news or events that may have affected Gamida Cell's share price include the publication of clinical trial data, regulatory updates, and announcements regarding partnerships or collaborations.

Looking beyond Gamida Cell's specific performance, it is essential to consider the broader industry in which the company operates. The field of cell therapy has been gaining significant attention and investment in recent years, driven by advancements in technology and the potential to revolutionize the treatment of various diseases, including cancer. Gamida Cell operates in a competitive landscape, with several other companies developing cell therapies and vying for market share.

As part of the industry analysis, it is crucial to evaluate Gamida Cell's competitive positioning and advantages relative to its peers. The company's proprietary NAM-based cell expansion technology platform sets it apart from competitors and positions it as a leader in the field. This technology allows for the expansion and enhancement of cells for transplantation, improving treatment outcomes and addressing critical unmet needs.

Gamida Cell's partnerships and collaborations with established pharmaceutical companies provide validation and access to resources that enhance its competitive advantage. These collaborations enable the company to leverage the expertise and resources of its partners to accelerate the development and commercialization of its cell therapy products.

While Gamida Cell has demonstrated growth and potential, it has risks and challenges. The biotechnology industry is highly regulated, and regulation changes or the regulatory environment can impact the development and approval of new therapies. The company must navigate complex and evolving regulatory pathways to successfully bring its products to market.

Additionally, Gamida Cell faces the challenge of staying ahead of the competition in a rapidly evolving field. Other companies also invest in cell therapies, and competitors' breakthroughs could threaten Gamida Cell's market position. Maintaining a robust research and development pipeline, protecting intellectual property, and securing strategic partnerships are vital for the company's long-term success.

GMDA Stock Price History

GMDA Stock News Headlines

Q4 2023 Gamida Cell Ltd Earnings Call
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Why Is Gamida Cell (GMDA) Stock Down 82% Today?
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Gamida Cell Annual Net Loss Narrows; To Be Taken Private
Gamida Cell Earnings Preview
Gamida Cell (GMDA) Earnings Dates & Reports
Gamida Cell Ltd. (GMDA)
Gamida Cell Ltd (GMDA)
Gamida Cell just downgraded at JMP Securities, here's why
Gamida Cell Actively Pursuing Strategic Alternatives - Quick Facts
Gamida Cell Actively Pursuing Strategic Alternatives
See More Headlines
Receive GMDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gamida Cell and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/14/2023
Today
3/27/2024
Next Earnings (Confirmed)
3/27/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:GMDA
Fax
N/A
Employees
143
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.75
High Stock Price Target
$6.00
Low Stock Price Target
$2.00
Potential Upside/Downside
+9,021.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
4 Analysts

Profitability

Net Income
$-79,380,000.00
Pretax Margin
-11,434.03%

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($0.11) per share

Miscellaneous

Free Float
98,492,000
Market Cap
$6.25 million
Optionable
Optionable
Beta
1.03
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Ms. Abigail L. Jenkins (Age 48)
    President, CEO & Director
    Comp: $554.05k
  • Ms. Michele Ilene Korfin M.B.A. (Age 52)
    R.Ph., Chief Operating & Chief Commercial Officer
    Comp: $606k
  • Dr. Ronit Simantov M.D. (Age 59)
    Chief Medical Officer & Chief Scientific Officer
    Comp: $592k
  • Mr. Joshua F. Patterson (Age 47)
    General Counsel & Chief Compliance Officer
    Comp: $479k
  • Ms. Mary Theresa Coelho M.B.A. (Age 61)
    CFO, Principal Financial Officer & Principal Accounting Officer
  • Ms. Linda Stamler
    Vice President of Marketing & Account Management
  • Ms. Penny Bushell
    Chief Human Resource Officer
  • Mr. Naftali Brikashvili CPA
    Senior Vice President Finance & Operations
  • Dr. Tracey Lodie Ph.D. (Age 54)
    Scientific Advisor & Consultant
  • Mr. Vladimir Melnikov
    Senior Vice President of Global Operations & Manufacturing

GMDA Stock Analysis - Frequently Asked Questions

Should I buy or sell Gamida Cell stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Gamida Cell in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" GMDA shares.
View GMDA analyst ratings
or view top-rated stocks.

What is Gamida Cell's stock price target for 2024?

4 analysts have issued 12 month target prices for Gamida Cell's stock. Their GMDA share price targets range from $2.00 to $6.00. On average, they expect the company's share price to reach $4.75 in the next year. This suggests a possible upside of 7,923.6% from the stock's current price.
View analysts price targets for GMDA
or view top-rated stocks among Wall Street analysts.

How have GMDA shares performed in 2024?

Gamida Cell's stock was trading at $0.4127 at the start of the year. Since then, GMDA shares have decreased by 85.7% and is now trading at $0.0592.
View the best growth stocks for 2024 here
.

Are investors shorting Gamida Cell?

Gamida Cell saw a increase in short interest in March. As of March 15th, there was short interest totaling 10,960,000 shares, an increase of 9.8% from the February 29th total of 9,980,000 shares. Based on an average trading volume of 3,020,000 shares, the days-to-cover ratio is currently 3.6 days.
View Gamida Cell's Short Interest
.

How were Gamida Cell's earnings last quarter?

Gamida Cell Ltd. (NASDAQ:GMDA) released its quarterly earnings data on Monday, August, 14th. The company reported ($0.31) EPS for the quarter, missing analysts' consensus estimates of ($0.18) by $0.13. During the same period in the previous year, the business earned ($0.31) earnings per share.

What ETF holds Gamida Cell's stock?

ARK Israel Innovative Technology ETF holds 1,466,958 shares of GMDA stock, representing 1.97% of its portfolio.

What other stocks do shareholders of Gamida Cell own?
When did Gamida Cell IPO?

Gamida Cell (GMDA) raised $50 million in an initial public offering on Friday, October 26th 2018. The company issued 3,600,000 shares at $13.00-$15.00 per share. BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO and Needham & Company Oppenheimer & Co. was co-manager.

Who are Gamida Cell's major shareholders?

Gamida Cell's stock is owned by a variety of retail and institutional investors. Top institutional investors include ARK Investment Management LLC (2.03%), Nantahala Capital Management LLC (0.76%), Corsair Capital Management L.P. (0.29%), Stock Yards Bank & Trust Co. (0.09%), Cambridge Investment Research Advisors Inc. (0.07%) and Citadel Advisors LLC (0.00%). Insiders that own company stock include Abigail L Jenkins and Stephen T Wills.
View institutional ownership trends
.

How do I buy shares of Gamida Cell?

Shares of GMDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GMDA) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners